/
MTVA
$1.49+$0.06 (+4.20%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.4M
5M shares
52-week range
$0.97 – $19.03
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
250.63%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-26.56
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $67.0K | $72.0K | $28.0K | $7.0K | $24.0K | $19.0K |
| Gross profit | $0 | $0 | −$67.0K | −$72.0K | −$28.0K | −$7.0K | −$24.0K | −$19.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $13.9M | $17.5M | $21.9M | $6.5M | $2.8M | $9.2M | $21.5M | $6.8M |
| Operating income | −$15.5M | −$20.2M | −$29.7M | −$15.3M | −$19.6M | −$15.9M | −$28.8M | −$13.7M |
| EBITDA | −$15.5M | −$20.2M | −$29.7M | −$15.2M | −$11.8M | −$12.5M | −$27.6M | −$13.0M |
| Net income | −$15.5M | −$21.3M | −$29.7M | −$15.3M | −$14.0M | −$12.5M | −$27.6M | −$13.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -112860.00 | -10771.20 | -4831.20 | -1742.40 | -477.84 | -27.06 | -39.16 | -7.35 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-2.49 | $-3.30–$-1.67 | 2 |
| 2027 | $0 | $-2.41 | $-3.61–$-1.20 | 2 |
| 2028 | $0 | $-1.58 | $-2.43–$-0.88 | 3 |
| 2029 | $0 | $-1.37 | $-1.37–$-1.37 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$5.15
Price
$1.49
Implied upside
+245%
Peer comparison
MetaVia Inc. Common Stock
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
www.metaviatx.com- Employees
- 8
- IPO / List date
- Aug 4, 2016
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds MTVA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MTVA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-12-05 | 1-for-11reverse |
Recent trades on TradeandTell
No one on the platform has traded MTVA yet.
